Key result
Obesity linked to ~190% higher nsVT incidence in HFrEF patients on sacubitril/valsartan.
Why the study?
To compare clinical outcomes according to BMI among patients with HFrEF after initiating ARNI treatment.
Does obesity affect clinical outcomes, LVEF improvement, and arrhythmia incidence in HFrEF patients treated with sacubitril/valsartan?
Cohort (n=208)
No
Does obesity affect clinical outcomes, LVEF improvement, and arrhythmia incidence in HFrEF patients treated with sacubitril/valsartan?
In HFrEF patients treated with sacubitril/valsartan, obesity is associated with blunted LVEF recovery and a higher incidence of non-sustained ventricular tachycardia at 12 months compared to non-obese patients.
Answers are grounded in this paper and cite their sources.
May warrant arrhythmia monitoring in obese HFrEF patients on sacubitril/valsartan; leaves open whether BMI modifies treatment response.
Aim To compare clinical outcomes among patients with heart failure and reduced ejection fraction (HFrEF) according to body mass index (BMI) after initiating treatment with an angiotensin‐receptor neprilysin inhibitor (ARNI). Methods We gathered data from 2016 to 2020 at the University Medical Center Mannheim; 208 consecutive patients were divided into two groups according to BMI (< 30 kg/m 2 ; n = 116, ≥ 30 kg/m 2 ; n = 92). Clinical outcomes, including mortality rate, all‐cause hospitalizations and congestion, were systematically analysed. Results At the 12‐month follow‐up, the mortality rate was similar in both groups (7.9% in BMI < 30 kg/m 2 vs. 5.6% in BMI ≥ 30 kg/m 2 ; P = .76). All‐cause hospitalization before ARNI treatment was comparable in both groups (63.8% in BMI < 30 kg/m 2 vs. 57.6% in BMI ≥ 30 kg/m 2 ; P = .69). After ARNI treatment, the hospitalization rate was also comparable in both groups at the 12‐month follow‐up (52.2% in BMI < 30 kg/m 2 vs. 53.7% in BMI ≥ 30 kg/m 2 ; P = .73). Obese patients experienced more congestion compared with non‐obese patients at follow‐up, without statistical significance (6.8% in BMI < 30 kg/m 2 vs. 15.5% in BMI ≥ 30 kg/m 2 ; P = .11). Median left ventricular ejection fraction (LVEF) improved in both groups, but significantly more in non‐obese compared with obese patients at the 12‐month follow‐up (from 26% [3%‐45%] [min.‐max.] vs. 29% [10%‐45%] [min.‐max.] [ P = .56] to 35.5% [15%‐59%] [min.‐max.] vs. 30% [13%‐50%] [min.‐max.] [ P = .03], respectively). The incidence of atrial fibrillation (AF), non‐sustained (ns) and sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) was less in non‐obese than in obese patients after initiation of sacubitril/valsartan at the 12‐month follow‐up (AF: 43.5% vs. 53.7%; P = .20; nsVT: 9.8% vs. 28.4%; P = .01; VT: 14.1% vs. 17.9%; P = .52; VF: 7.6% vs. 13.4%; P = .23). Conclusions The incidence of congestion in obese patients was higher compared with non‐obese patients. LVEF improved significantly more in non‐obese compared with obese HFrEF patients. Furthermore, AF and the ventricular tachyarrhythmia rate were revealed more in obesity compared with those without obesity at the 12‐month follow‐up.
No takes yet. Share an insight, caveat, or question.
Abumayyaleh et al. (2023) conducted a cohort in heart failure with reduced ejection fraction (HFrEF) (n=208). Obesity (BMI ≥ 30 kg/m2) vs. Non-obesity (BMI < 30 kg/m2) was evaluated on non-sustained ventricular tachycardia (nsVT) (p=.01). In HFrEF patients treated with sacubitril/valsartan, obesity was associated with a higher incidence of non-sustained ventricular tachycardia compared to non-obese patients.
Synapse has enriched 10 related papers. Consider them for comparative context: